Recombinant Mouse Mitochondrial glutamate carrier 2 (Slc25a18)

What is SLC25A18 and what is its primary function in cellular metabolism?

SLC25A18, also known as Mitochondrial glutamate carrier 2 (GC-2) or Glutamate/H(+) symporter 2, is a member of the mitochondrial carrier family (TC 2.A.29). Its primary function is the transport of glutamate from the cytosol into the mitochondrial matrix with the concomitant import of a proton (symport system) . This transport mechanism is critical for maintaining nitrogen metabolism and mitochondrial function.

The protein facilitates the movement of glutamate across the mitochondrial inner membrane, coupling glutamate transport with proton movement to maintain mitochondrial pH and ionic balance . This transport function is essential for various metabolic pathways, particularly those involving amino acid metabolism and energy production.

What expression systems are commonly used for recombinant SLC25A18 production?

Recombinant mouse SLC25A18 is typically expressed in prokaryotic systems, with Escherichia coli being the most commonly used expression host. The protein is generally produced with an N-terminal His tag to facilitate purification . This expression system has been demonstrated to yield protein with greater than 90% purity, suitable for various experimental applications including SDS-PAGE analysis .

When expressing SLC25A18 in E. coli, researchers should optimize culture conditions including temperature, induction timing, and media composition to maximize protein yield while maintaining proper folding and function. The bacterial expression system is particularly advantageous for producing large quantities of the protein for structural studies and in vitro functional assays.

What is the tissue distribution pattern of SLC25A18 in mammals?

SLC25A18 demonstrates a tissue-specific expression pattern in mammals. It is predominantly expressed in the brain, liver, and testis, with comparatively lower expression levels in tissues such as the breast, lung, and colon . This tissue-specific distribution correlates with its functional role in nitrogen metabolism and specialized metabolic activities in these tissues.

In the brain specifically, SLC25A18 immunoreactivity has been observed in neuron outlines as demonstrated by immunohistochemical staining of rat brain sections . This neuronal expression pattern suggests important roles in glutamate metabolism within the central nervous system, potentially contributing to neurotransmitter recycling and energy metabolism in neurons.

What experimental approaches can be used to study SLC25A18 transport kinetics?

To study SLC25A18 transport kinetics, researchers should consider the following methodological approaches:

• Reconstituted Proteoliposome Assays: Purified recombinant SLC25A18 can be reconstituted into proteoliposomes to measure glutamate transport rates under various conditions. This method allows for the determination of kinetic parameters such as Km and Vmax values.

• Mitochondrial Isolation and Transport Assays: Isolate mitochondria from cells expressing recombinant SLC25A18 and measure glutamate uptake using radiolabeled substrates or fluorescent probes.

• Patch-Clamp Electrophysiology: For direct measurement of transport-associated currents in cells or reconstituted membrane systems expressing SLC25A18.

• Fluorescence-Based Transport Assays: Utilizing fluorescent glutamate analogs or pH-sensitive probes to monitor transport activity in real-time.

When performing these experiments, it is crucial to control for membrane potential and pH gradients, as SLC25A18 functions as a proton symporter . Temperature, substrate concentration, and the presence of potential inhibitors should be systematically varied to characterize the transport properties fully.

How can researchers effectively validate SLC25A18 antibodies for experimental applications?

Validation of antibodies against SLC25A18 requires a multi-step approach to ensure specificity and reliability:

• Western Blot Analysis with Tissue Panels: Test the antibody against tissues known to express SLC25A18 (brain, liver, testis) and those with lower expression (breast, lung, colon). Mouse brain, rat brain, and rat heart lysates have been successfully used to detect SLC25A18 .

• Blocking Peptide Controls: Always perform parallel experiments using the antibody pre-incubated with a specific blocking peptide. As demonstrated in previous studies, antibody specificity can be confirmed when pre-incubation with the blocking peptide (e.g., peptide corresponding to amino acid residues 95-110 of mouse SLC25A18) suppresses the signal .

• Cell Line Validation: Human cell lines such as glioblastoma U-87 MG and neuroblastoma SH-SY5Y have been used successfully to detect SLC25A18 .

• Immunohistochemistry Controls: For IHC applications, include positive controls (tissues with known expression) and negative controls (antibody omission and blocking peptide pre-incubation). Immunohistochemical staining of perfusion-fixed frozen rat brain sections has shown SLC25A18 immunoreactivity in neuron outlines that can be suppressed with blocking peptide .

What methodologies are recommended for studying the role of SLC25A18 in disease models?

For investigating SLC25A18's role in disease pathology, researchers should consider these methodological approaches:

• Gene Expression Modulation:

  • RNA Interference: Design specific shRNAs targeting SLC25A18 for knockdown studies. Cell lines like SW620 and HS675.T have been successfully transduced with lentivirus containing SLC25A18-shRNAs .

  • Overexpression: Generate stable cell lines overexpressing SLC25A18 using lentiviral vectors. HCT116 and LOVO cell lines have been effectively transduced with lenti-oe SLC25A18 .

• Expression Analysis:

  • RT-PCR: Using primers specific to SLC25A18 (e.g., forward 5'-GTGTTCCCCATCGACTTGG-3' and reverse 5'-CACGACCTGGCACATCCC-3') .

  • Western Blotting: Using validated antibodies against SLC25A18 .

  • Immunohistochemistry: For tissue sections, using standardized scoring systems where intensity is scored (0-3) and percentage of positive cells is quantified (0-4) .

• Bioinformatic Analysis:

  • TCGA and GEO Database Mining: For correlating SLC25A18 expression with clinical outcomes in various diseases .

  • Gene Set Enrichment Analysis (GSEA): To determine biological functions and signaling pathways associated with SLC25A18, using tools like GSEA version 2.3.3 .

• Functional Assays:

  • Metabolic Phenotyping: Measure glutamate metabolism, mitochondrial respiration, and glycolytic activity in cells with modified SLC25A18 expression.

  • In vivo Models: Develop and characterize mouse models with altered SLC25A18 expression to study systemic effects.

What approaches can be used to study the structure-function relationships of SLC25A18?

To investigate structure-function relationships of SLC25A18, researchers should consider:

• Site-Directed Mutagenesis: Generate specific mutations in key residues of recombinant SLC25A18 to identify amino acids critical for:

  • Substrate binding and specificity

  • Transport mechanism

  • Protein-protein interactions

  • Regulatory modifications

• Chimeric Protein Construction: Create chimeric proteins between SLC25A18 and related carriers (e.g., SLC25A22) to identify domains responsible for specific functional properties.

• Structural Biology Approaches:

  • X-ray Crystallography: Optimize conditions for crystallizing the recombinant protein, potentially using lipidic cubic phase methods suitable for membrane proteins.

  • Cryo-Electron Microscopy: For high-resolution structural determination without crystallization.

  • NMR Spectroscopy: For analyzing dynamics and ligand interactions in solution.

• Computational Modeling:

  • Homology Modeling: Based on structures of related mitochondrial carriers.

  • Molecular Dynamics Simulations: To predict conformational changes during transport cycles.

  • Virtual Screening: To identify potential inhibitors or modulators.

These approaches would benefit from the availability of high-purity recombinant SLC25A18 protein, such as the >90% pure preparations described in the literature .

How can researchers investigate the potential role of SLC25A18 in cancer metabolism?

Recent research has implicated SLC25A18 in cancer, particularly colorectal cancer (CRC) . To investigate its role in cancer metabolism, researchers should consider these methodological approaches:

• Expression Analysis in Clinical Samples:

  • Perform immunohistochemical staining on cancer tissue microarrays

  • Quantify expression using standardized scoring systems (intensity × percentage of positive cells)

  • Compare expression between tumor and adjacent normal tissues

  • Correlate expression levels with clinical outcomes using Kaplan-Meier survival analysis

• Metabolic Phenotyping of Cancer Cells:

  • Measure glutamate uptake and metabolism in cancer cells with modified SLC25A18 expression

  • Analyze impacts on oxidative phosphorylation and glycolytic metabolism using Seahorse XF analyzers

  • Evaluate effects on mitochondrial membrane potential and reactive oxygen species production

  • Assess metabolic reprogramming using metabolomics approaches

• Molecular Pathway Analysis:

  • Conduct Gene Set Enrichment Analysis (GSEA) to identify pathways associated with SLC25A18 expression

  • Use RNA-seq and proteomic analysis to identify downstream effectors

  • Perform ChIP-seq to identify transcription factors regulating SLC25A18 expression

  • Apply network analysis to place SLC25A18 in the context of cancer-related pathways

• Functional Validation in Cancer Models:

  • Develop stable cell lines with SLC25A18 knockdown or overexpression

  • Assess effects on cell proliferation, migration, invasion, and colony formation

  • Evaluate tumor growth and metastasis using xenograft models

  • Test combination with metabolic inhibitors or standard chemotherapeutic agents

What are the optimal storage and handling conditions for recombinant SLC25A18 protein?

For maintaining optimal activity and stability of recombinant SLC25A18 protein, researchers should follow these evidence-based handling protocols:

• Storage Conditions:

  • Store lyophilized protein at -20°C to -80°C upon receipt

  • For long-term storage, store in aliquots to avoid repeated freeze-thaw cycles, which can compromise protein integrity

  • Working aliquots can be stored at 4°C for up to one week

• Reconstitution Protocol:

  • Briefly centrifuge the vial prior to opening to bring contents to the bottom

  • Reconstitute in deionized sterile water to a concentration of 0.1-1.0 mg/mL

  • Add glycerol to a final concentration of 5-50% for storage stability

  • The recommended default final concentration of glycerol is 50%

• Buffer Composition:

  • Optimal buffer composition is Tris/PBS-based buffer with 6% Trehalose, pH 8.0

  • This formulation helps maintain protein stability and solubility

• Quality Control:

  • Verify protein purity using SDS-PAGE analysis (recommended purity >90%)

  • For Tris-Glycine gel electrophoresis, use discontinuous SDS-PAGE with 5% enrichment gel and 15% separation gel under reducing conditions

What experimental controls are essential when using recombinant SLC25A18 in functional assays?

When designing experiments with recombinant SLC25A18, researchers should include these critical controls:

• Negative Controls:

  • Empty vector-expressed protein preparation to control for expression system artifacts

  • Heat-denatured SLC25A18 to demonstrate specificity of transport activity

  • Competitive inhibitors of glutamate transport to confirm specificity

• Positive Controls:

  • Known functional mitochondrial carrier proteins expressed and purified under identical conditions

  • Commercially validated glutamate transport systems

• Validation Controls:

  • Western blot confirmation of protein identity and integrity before functional assays

  • Mass spectrometry verification of purified protein

  • Activity assays to confirm functional state before complex experiments

• System-specific Controls:

  • For proteoliposome assays: protein-free liposomes to control for non-specific leakage

  • For cell-based assays: untransfected cells to establish baseline transport

  • For binding assays: non-specific binding determination using excess unlabeled substrate

What are the emerging research areas involving SLC25A18 in neurological disorders?

Given SLC25A18's high expression in the brain and its role in glutamate transport, several promising research avenues exist:

• Neurodegenerative Diseases:

  • Investigate SLC25A18 expression and function in Alzheimer's, Parkinson's, and Huntington's disease models

  • Examine correlations between SLC25A18 genetic variants and disease susceptibility or progression

  • Explore the impact of disease-associated protein aggregates on SLC25A18 function

• Excitotoxicity Mechanisms:

  • Study how SLC25A18 contributes to glutamate homeostasis during excitotoxic events

  • Develop experimental models to test SLC25A18 modulation as a neuroprotective strategy

  • Investigate interactions between SLC25A18 and glutamate receptors or transporters

• Mitochondrial Dysfunction in Neurological Disorders:

  • Characterize how SLC25A18 dysfunction affects mitochondrial metabolism in neurons

  • Examine relationships between SLC25A18 and mitochondrial quality control mechanisms

  • Develop therapeutic approaches targeting SLC25A18 to improve mitochondrial function

• Comparative Analysis with SLC25A22:

  • Investigate functional redundancy and specificity between the two mitochondrial glutamate carriers

  • Analyze tissue-specific expression patterns and differential regulation

  • Examine whether SLC25A18 can compensate for SLC25A22 deficiency in disease models

How might advances in structural biology techniques impact our understanding of SLC25A18?

Recent technological advances offer new opportunities for understanding SLC25A18 structure and function:

• Cryo-Electron Microscopy Advancements:

  • Single-particle cryo-EM methods now achieve resolutions suitable for membrane protein structural determination

  • These techniques could reveal the three-dimensional structure of SLC25A18 in different conformational states

  • Understanding these states would provide insight into the transport mechanism

• Integrative Structural Biology:

  • Combining X-ray crystallography, NMR spectroscopy, and computational modeling

  • These complementary approaches can provide a more complete picture of protein dynamics

  • Time-resolved structural studies could capture intermediate states during transport

• In-cell Structural Biology:

  • Emerging techniques for studying protein structure in native cellular environments

  • These approaches could reveal how SLC25A18 structure is affected by the mitochondrial membrane environment

  • Potential to discover unexpected interactions with other mitochondrial proteins

• Structure-Based Drug Design:

  • High-resolution structures would enable virtual screening for SLC25A18 modulators

  • Fragment-based approaches could identify novel binding sites

  • Structure-activity relationship studies could guide development of specific inhibitors or activators